Metagenomi Therapeutics announced it will present preclinical data on MGX-001, a novel one-time gene therapy for hemophilia A, at the 68th ASH Annual Meeting. MGX-001 uses targeted genome editing to insert the Factor VIII gene, potentially offering durable, lifelong treatment from a single dose. The company plans to start global clinical trials in 2027, pending regulatory approval, aiming to reduce treatment burdens and bleeding risks for patients. This presentation highlights promising efficacy, safety, and durability results that support MGX-001's development as a new standard of care.
Metagenomi Therapeutics' gene therapy development is the subject, with Pluang providing a snapshot of the health sector as of Nov 04, 2026 20:41 WIB: Of 150 priced health-sector US stocks, 127 rose and 19 fell. CVS Health Corp traded at USD 86.90 with a 4.93% decline and a typical hold time of 81 days, contrasting with Tilray Brands Inc at USD 2.78, which rose 4.91% but saw 96% sell activity and a shorter hold time of 32 days. Alcon AG gained 4.34% to USD 75.51, with 91% sell orders and a hold time of 72 days.
The global AI accelerator market is projected to grow from $151 billion in 2025 to $443 billion by 2030, with a compound annual growth rate of about 24%. This expansion is fueled by the rise of generative AI, large language models, and increased inve...
No7 Software has enhanced its Anchor Loyalty & Rewards app by integrating Shopify POS, allowing merchants to run a unified loyalty program across online stores and physical shops. Customers now maintain a single points balance, tier status, and refer...
A growing town replaced its inefficient IT request process of spreadsheets and emails with a centralized Microsoft Power Apps hub developed by eSoftware Associates. This hub integrates project intake, risk assessment, and PMO scoring into one platfor...
Kelly Technology + Motion Recruitment, a division of Kelly Services, has been recognized as a Leader on Everest Group's 2026 U.S. IT Contingent Talent and Strategic Solutions PEAK Matrix® for its expertise in specialized IT staffing, consulting, and ...
Sutro Biopharma, a clinical-stage oncology company specializing in antibody drug conjugates (ADCs), announced its participation in several investor conferences in November and December 2026, including events hosted by Stifel, Truist Securities, UBS, ...
